266 544

Cited 78 times in

Zinc is required in pyrrolidine dithiocarbamate inhibition of NF-kappaB activation

DC Field Value Language
dc.contributor.author김철훈-
dc.contributor.author안영수-
dc.date.accessioned2020-01-23T05:28:52Z-
dc.date.available2020-01-23T05:28:52Z-
dc.date.issued1999-
dc.identifier.issn0014-5793-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/174319-
dc.description.abstractPyrrolidine dithiocarbamate (PDTC) is a potent inhibitor of nuclear factor kappa B (NF-kappaB) activation. PDTC inhibited basal NF-kappaB activity of endothelial cells. PDTC, however, failed to inhibit basal NF-kappaB activity after withdrawal of serum in the media, and the inhibitory effect of PDTC could be restored by addition of zinc. When various preparations of metal ion-EDTA were tested with PDTC in serum-containing media, only Zn-EDTA failed to block the inhibitory effect of PDTC. The dependence on zinc was also noted in PDTC inhibition of NF-kappaB stimulated by TNF alpha. These facts suggest that zinc is required for PDTC inhibition of NF-kappaB activation.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherJohn Wiley & Sons Ltd.-
dc.relation.isPartOfFEBS Letters-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHAnimals-
dc.subject.MESHAntioxidants/metabolism*-
dc.subject.MESHAntioxidants/pharmacology-
dc.subject.MESHCations-
dc.subject.MESHCattle-
dc.subject.MESHCells, Cultured-
dc.subject.MESHMetals-
dc.subject.MESHNF-kappa B/antagonists & inhibitors*-
dc.subject.MESHPyrrolidines/metabolism*-
dc.subject.MESHPyrrolidines/pharmacology-
dc.subject.MESHThiocarbamates/metabolism*-
dc.subject.MESHThiocarbamates/pharmacology-
dc.subject.MESHTumor Necrosis Factor-alpha/pharmacology-
dc.subject.MESHZinc/metabolism*-
dc.titleZinc is required in pyrrolidine dithiocarbamate inhibition of NF-kappaB activation-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Pharmacology (약리학교실)-
dc.contributor.googleauthorChul Hoon Kim-
dc.contributor.googleauthorJoo Hee Kim-
dc.contributor.googleauthorChung Y. Hsu-
dc.contributor.googleauthorY S Ahn-
dc.identifier.doi10.1016/s0014-5793(99)00390-7-
dc.contributor.localIdA01057-
dc.contributor.localIdA02246-
dc.relation.journalcodeJ00890-
dc.identifier.eissn1873-3468-
dc.identifier.pmid10225421-
dc.contributor.alternativeNameKim, Chul Hoon-
dc.contributor.affiliatedAuthor김철훈-
dc.contributor.affiliatedAuthor안영수-
dc.citation.volume449-
dc.citation.number1-
dc.citation.startPage28-
dc.citation.endPage32-
dc.identifier.bibliographicCitationFEBS Letters, Vol.449(1) : 28-32, 1999-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Pharmacology (약리학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.